Pulse Biosciences Q1 net loss $10.1M; FDA clears percutaneous electrode; plans $60M rights offering

PULSE BIOSCIENCES, INC.

FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for soft tissue ablation in percutaneous and intraoperative procedures.
CellFX nsPFA Cardiac Clamp 510(k) process ongoing; FDA requests clinical data; feasibility study submitted in Netherlands.
Board approved rights offering of up to $60M in units; record date moved to mid-June; fully subscribed adds $66M warrants.
GAAP net loss Q1 2024 $10.1M vs $9.8M year ago; cash $34.9M (down from $44.4M Dec 31, 2023).
Non-GAAP net loss $8.1M vs $8.6M prior year; Q1 cash used $9.5M including $2M annual bonus payouts.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

PULSE BIOSCIENCES, INC. reported the first quarter ended March 31, 2024 results: net income GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three mon.

Period: the first quarter ended March 31, 2024
Net income: GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three mon
Result: reported results

Exact text from the filing

Pulse Biosciences, Inc. (the "Company") announced its financial and operational results for the fiscal quarter ended March 31, 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-015083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.